Therefore, m6Ascore could be utilized to predict the effectiveness of chemotherapy and the patient’s clinical response to anti-PD1 and anti-CTLA4 immunotherapy for NSCLC, in addition to being used as an independent prognostic biomarker to predict patients’ survival. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.